DaVita Beat Q2 EPS, but the Stock Still Looks Cheap if You Ignore the Noise

DaVita beat Q2 estimates, but the sell-off points to a bigger concern

DaVita posted a solid second-quarter earnings beat, yet the market still sold the stock. Adjusted EPS of $4.02 beat the $3.84 consensus by $0.18, but shares fell another 7.05% after hours to $211.91. That reaction suggests investors were more focused on margin pressure, weaker revenue per treatment, and a softer second-half outlook than on the headline beat.

That does not automatically make the stock a buy. It does, however, create an interesting setup: if management can show that the mix and cost issues are temporary while guidance holds, the post-earnings drop could look more like a repricing opportunity than a warning about a broken business.

What held up in the quarter

The core business remained intact. DaVita reported $3.554 billion of revenue, $579 million of operating income, $4.02 of diluted EPS, $490 million of operating cash flow, and $256 million of free cash flow. It also reconfirmed full-year guidance, including a $14.65 adjusted EPS midpoint and $2.2 billion adjusted operating income midpoint.

There was also a meaningful clinical signal. Treatment volume rose 56 basis points from a year earlier, and volume growth acceleration was primarily driven by sustained improvements in patient mortality. That matters because it points to real clinical execution rather than artificial demand, and better survival can extend the revenue contribution of each patient over time.

Where the margin pressure is coming from

The market's concern was not demand collapse. It was the quality of that demand.

Management said revenue per treatment declined sequentially due to lower commercial mix following the expiration of ACA subsidies and lower sequential revenue contribution from phosphate binders. At the same time, patient care cost per treatment also remained elevated year to date. That is a mix-and-cost squeeze, not a collapse in volume.

The operating picture still looked healthy overall, but not cleanly improving. U.S. dialysis operating income remained relatively flat year-over-year as treatment growth was offset by elevated cost per treatment and a 10% increase in G&A spending. In other words, the business kept performing, but the margin story is still being earned rather than assumed.

Why the stock can still look attractive

Management is also pivoting toward areas that could help both outcomes and economics. Management is pivoting toward middle molecule clearance technology, specifically expanded hemodialysis (HD), which offers mortality benefits without requiring significant new capital investment in machines. And the recent FDA approval of new expanded HD dialyzers from NIPRO is expected to materially improve market supply and economics for advanced dialysis treatments.

That does not guarantee near-term margin improvement. But it does give investors a reason to view this quarter as an interim setup rather than a final verdict on the business.

Valuation still leaves room for a rerating

Even after a 32.9% year-to-date rebound, DaVita a valuation score of 5 out of 6. The same source says DaVita Discounted Cash Flow (DCF) Analysis points to a meaningful discount. That does not mean the shares will bounce immediately. It does suggest the market is still pricing in a messy recovery rather than a fully repaired margin profile.

What matters next

The next earnings call is scheduled for Oct. 28, 2026. The key question is no longer whether DaVita can post a decent quarter; it is whether it can hold its full-year guardrails while the mix and cost pressures ease.

What would support the bull case

• Guidance remains intact.
• Revenue per treatment stops weakening materially.
• Cost per treatment comes back down from current levels.
• Expanded HD and other clinical initiatives begin to show an operating benefit.

What would weaken the thesis

• revenue per treatment declined sequentially turns into a sustained downward trend.
• patient care cost per treatment also remained elevated year to date becomes a longer-running problem.
• Management lowers a midpoint of $14.65 for adjusted EPS and $2.2 billion for adjusted operating income.

For now, the stock looks undervalued only if you believe this quarter reflects a temporary mix penalty rather than a more permanent margin problem.